Neuroendocrine tumors (NETs) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Neuroendocrine tumors are cancers that begin in specialized cells called neuroendocrine cells. Neuroendocrine cells and nerve and hormone-producing cells have similar traits. Of all malignant tumors, neuroendocrine tumors make up just 0.05%. Depending on where the appendix is, it has an incidence of about 2/100,000 and mostly affects women under 50. Surgical removal of the primary tumor is the first approach frequently advised for patients with localized NETs. A neuroendocrine tumor is removed surgically in order to either completely remove it or lessen its impact.

Description

The specialized cells called neuroendocrine cells are where neuroendocrine tumors, also known as cancers, originate. Neuroendocrine cells are similar to nerve and hormone-producing cells in their characteristics. The body can develop neuroendocrine tumors anywhere, though they are uncommon. The majority of neuroendocrine tumors are found in the pancreas, lungs, appendix, small intestine, rectum, and appendix.

Neuroendocrine tumors (NETs)(Epidemiology)

Only 0-15% of all malignant tumors are neuroendocrine tumors. Depending on where the appendix is located, its incidence is around 2/100,000 and it primarily affects women under 50. The lung (22-27%) and gastrointestinal tract (62-67%) are the two primary sites. 12-22% of cases that are present have metastatic disease. The incidence has been increasing in recent decades. This might result from increased awareness, better diagnostic equipment, or a definitional change. The majority of neuroendocrine tumors are sporadic, but clustering within families and association with multiple endocrine neoplasia type 1 syndrome are known. Additionally, although the numbers are small, there has been information about an increased risk of secondary cancers. Stage primarily affects the 5-year survival rate: local disease accounts for 93%, regional disease for 74%, and metastatic disease for 19%. Since 1992, when octreotide treatment became widely accessible in The Netherlands, survival rates for patients with metastatic disease have risen.

Neuroendocrine tumors (NETs)-Current Market Size & Forecast Trends

The market for neuroendocrine tumors (NETs) is projected to experience significant growth, with estimates indicating a current value of approximately USD 2.04 billion in 2024, expected to reach around USD 5.62 billion by 2037, reflecting a compound annual growth rate (CAGR) of about 8.1% during the forecast period from 2025 to 2037. This growth is driven by the increasing incidence of NETs, advancements in treatment options such as somatostatin analogs and peptide receptor radionuclide therapy (PRRT), and heightened awareness of these rare tumors. The rising demand for effective therapies, coupled with ongoing research and development initiatives, is expected to further enhance market dynamics. Additionally, regions like Europe and Asia-Pacific are anticipated to contribute significantly to market expansion due to increased healthcare spending and improved diagnostic capabilities. Overall, the NETs market is well-positioned for substantial growth through 2035, supported by innovative treatment strategies and a growing emphasis on addressing this unique category of cancers.

Surgery to remove the primary tumor is the first approach frequently recommended for patients with localized NETs. Surgery attempts to either completely remove or lessen the burden of a neuroendocrine tumor. Rectal NETs smaller than 10 mm are thought to have a low risk of lymphovascular and muscolaris invasion, rarely show malignant potential, and should be completely removed endoscopically. The risk of metastases for these tumors has been estimated to be less than 3%. Rectal NETs less than 10 mm can be successfully treated endoscopically or by local excision because they rarely metastasize, are typically low grade, and make up 80% of all rectal NETs diagnosed. EMR-L should be used to treat small rectal NETs first because it is less time-consuming than ESD, safe, and effective. ESD ought to be used as a fallback therapy when EMR-L is not appropriate. Because they are more likely to experience muscolaris and lymphovascular invasion, rectal NETs with a diameter of 10-20 mm have a worse prognosis than those with a diameter of 10 mm. Endoscopic, transanal, or radical surgery can be used to remove these tumors surgically, but the results have a worse prognosis. Rectal NETs larger than 20 mm are candidates for radical rectal resection and lymph node dissection because of their high metastatic potential. Chemotherapy for NETs can be used alone or in addition to other treatments. Chemoembolization, in which chemotherapy medications are directly injected into the tumor, may be an option if the disease has spread to the liver. Hormone therapy for NETs typically slows tumor growth rather than causing tumors to shrink. It mainly serves to control hormone-like substances released from NETs. Some of the symptoms that these medications frequently cause could be alleviated by hormone therapy. The goal of NET hormone therapy is to regulate the hormone somatostatin, which is involved in the regulation of other hormones like insulin. Radiation therapy is frequently employed when a neuroendocrine tumor has metastasized or is in a challenging location for surgery. CyberKnife(R) is a non-invasive treatment option for some patients that allows our radiation oncologists to target NETs with high radiation doses. Modern options for treating liver metastases include TheraSphere(R) and SIR-Spheres(R), which deliver radiation to tumors there.

Report Highlights

Neuroendocrine tumors (NETs)- Current Market Trends

Neuroendocrine tumors (NETs)- Current & Forecasted Cases across the G8 Countries

Neuroendocrine tumors (NETs)- Market Opportunities and Sales Potential for Agents

Neuroendocrine tumors (NETs)- Patient-based Market Forecast to 2035

Neuroendocrine tumors (NETs)- Untapped Business Opportunities

Neuroendocrine tumors (NETs)- Product Positioning Vis-a-vis Competitors' Products

Neuroendocrine tumors (NETs)- KOLs Insight